Singapore Expands Pneumococcal Vaccine Options for Residents

The Ministry of Health (MOH) in Singapore has announced the inclusion of a new pneumococcal vaccine, PCV20, in the National Adult Immunisation Schedule (NAIS). This decision, effective from August 29, 2023, grants subsidies for eligible Singaporeans and permanent residents, allowing them to use their Medisave accounts to cover costs associated with this vaccination.

PCV20, developed by Pfizer, is a 20-valent pneumococcal conjugate vaccine that provides protection against a broader range of pneumococcal strains compared to previous vaccines. It protects against seven additional strains compared to the 13-valent vaccine, PCV13. The Health Sciences Authority approved PCV20 in March 2023, marking Singapore as the first country in Southeast Asia to offer this vaccine.

Subsidized Costs and Eligibility

From Monday, eligible individuals can expect to pay between S$17 (approximately US$13) and S$68 for a full single-dose course of PCV20 at participating Community Health Assist Scheme (CHAS) general practitioner clinics. The final cost will vary based on CHAS card status and whether the individual belongs to the Pioneer Generation or Merdeka Generation.

For those enrolled in the Healthier SG initiative, the vaccine will be fully subsidised at their designated clinics. Similarly, costs at polyclinics and MOH-funded long-term care institutions will reflect the same range, contingent on per capita household income or generational status. Permanent residents will face a higher cost, expected to be around S$102.

MOH recommends PCV20 for all adults aged 65 years and older and for those aged 18 to 64 at higher risk of severe pneumococcal disease. Individuals who have previously received PCV13 and/or PPSV23 should consult their doctors regarding the necessity of PCV20.

Additional Vaccinations Included

In a related announcement, MOH confirmed that Shingrix, the only vaccine registered for shingles protection by the Health Sciences Authority, will also be included in the NAIS starting from September 1, 2023. Shingrix is recommended for adults aged 60 and older, and for immunocompromised individuals aged 18 to 59.

The recommended vaccination schedule for Shingrix consists of two doses, administered with an interval of two to six months. By mid-2026, the MediSave500/700 accounts will be usable to cover the post-subsidy costs for both PCV20 and Shingrix vaccines. Furthermore, seniors aged 60 and above who qualify for these vaccines may utilize the Flexi-MediSave option.

This initiative by the Ministry of Health aims to enhance public health by providing broader access to essential vaccinations, thereby addressing the growing health needs of Singapore’s aging population.